ObsEva Presents Linzagolix Data From Uterine Fibroid Trials

ObsEva SA OBSV has announced data from PRIMROSE (1 and 2) Phase 3 study of linzagolix for uterine fibroids.
The data were presented at the American Society for Reproductive Medicine (ASRM) 2021 Scientific Congress & Expo.
Related: ObsEva Files US Application For Linzagolix For Uterine Fibroids.
Once-daily treatment of 200 mg linzagolix without Hormonal Add-Back Therapy (ABT) reduced uterine and fibroid volume by 39% and 49%, respectively, after 24 weeks.
However, co-administration of hormonal ABT after 24 weeks counteracted the uterine volume reducing effects at 52 weeks, corresponding to a 21% reduction.
ObsEva also presented final data from the linzagolix study for severe adenomyosis (breaking of the inner lining of the uterus).
A high dose of 200 mg linzagolix reduced uterine volume by 55% from baseline at 12 weeks and 32% at 24 weeks after continued treatment with 100 mg linzagolix.
Pelvic pain was markedly reduced at 12 and 24 weeks, with initial reduction signs after four weeks.
Overall, significant improvements in quality of life were reported.
Price Action: OBSV shares traded higher by 0.73% at $2.76 premarket on the last check Wednesday.